We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander Kutikov

Alexander Kutikov MD, FACS

Associate Professor of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

Dr. Kutikov is a board certified, academic urologic surgical oncologist, who treats tumors of the adrenal, kidney, prostate, bladder, ureter, testis, and other genitourinary organs, using minimally invasive (robotic/laparoscopic) and traditional surgical techniques: https://www.foxchase.org/alexander-kutikov
 
Dr. Kutikov's current research interests include understanding renal/prostatic carcinogenesis, risk-stratification of surgical outcomes, and quantification of competing risks: http://www.fccc.edu/research/pid/kutikov/pub.html

Dr. Kutikov has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care. He is a co-founder of VisibleHealth, Inc and UrologyMatch, LLC: http://www.visiblehealth.com

Recent Contributions to PracticeUpdate:

  1. Risk Factors for Peritoneal Carcinomatosis Following Open Radical Cystectomy
  2. Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism
  3. Close Proximity to the Collecting System Increases Risk of Malignancy in Small Renal Tumors
  4. Incidence of Visible Hematuria Among Antithrombotic Agents
  5. Robot-Assisted Adrenalectomy vs Open Adrenalectomy
  6. Assessment of Cancer-Specific Mortality After Tumor Ablation vs Observation for Kidney Cancer
  7. A Nomogram for the Prediction of Indolent Renal Tumors
  8. Differentiation of Lipid-Poor Adrenal Adenomas From Non-Adenomas With Magnetic Resonance Imaging
  9. Pazopanib in Patients With Localized RCC to Optimize Preservation of Renal Parenchyma
  10. Presurgical Sunitinib Reduces Tumor Size and May Facilitate Partial Nephrectomy in Patients With Renal Cell Carcinoma

Most Read This Week

Recently Updated